Iconovo And Amneal Collaborate On Symbicort Rival
Planning Development Program Following Iconovo’s Pilot Study
Iconovo has brought Amneal on board as a partner to help develop a generic version of AstraZeneca’s Symbicort respiratory brand, as the Swedish inhalation specialist prepares to make major investments in the project.
You may also be interested in...
In the wake of a favorable US Court of Appeals for the Federal Circuit decision, Viatris has won FDA approval for the first generic Symbicort product. The ANDA sponsor’s management had recently declared itself “ready to launch if the opportunity presents itself in 2022.”
Amneal reported a 20% drop in sales in the fourth quarter of 2019, primarily due to lower turnover from its generics business. The company’s co-CEOs are trying to revitalize the company and have launched 15 new products since returning midway through last year.
With multiple Humira biosimilars slated for launch in the US next year, some simultaneously, a Vizient survey provides some insights into what could be the most important differentiating aspects. Generics Bulletin speaks to Steven Lucio, Vizient senior principal of pharmacy solutions, about the findings.